PanGenomic Health Expands NaraCare.AI Platform with Launch of DNA Testing Program

Executive Summary

• PanGenomic Health announced the launch of its Agenta DNA testing program, integrated with the Nara.Care AI platform for personalized wellness.
• The DNA test kits will be sold to Canadian consumers this quarter via the Agenta Health e‑commerce site, with a planned U.S. rollout in early 2026.
• The initiative aims to enrich the AI platform with genetic data to deliver actionable insights on diet, fitness, metabolism, brain function and overall health.

Key Details

• Program Launch: Introduction of Agenta branded DNA testing kits as part of the Nara.Care AI platform.
• Market Roll‑out: Initial sales in Canada this quarter; expansion into the United States targeted for early 2026.
• Distribution Channel: Kits available for purchase on the Agenta Health e‑commerce site (www.agentahealth.store).
• Strategic Partner: Collaboration with a leading developer of DNA testing technologies (partner not named).
• Platform Integration: Genetic data from Agenta tests will feed into Nara.Care AI to generate personalized wellness recommendations covering diet, fitness, metabolism, brain function and overall health.
• Data Privacy: Company commits to implementing safeguards to protect the privacy of genomic and health data.
• Leadership Quote: “We believe consumers are looking for better information about their unique health situation…the foundation of our NaraCare.AI platform is personalization…” – Maryam Marissen, President & CEO.

Notable Quotes

“The foundation of our NaraCare.AI platform is personalization, and there is no better baseline for that foundation than incorporating the unique genetic makeup of each individual.” – Maryam Marissen, President & CEO

All boilerplate, forward‑looking disclaimer, and contact information have been omitted per instructions.